Post Operative Urinary Retention (POUR) Following Thoracic Oncological Surgery
Urinary Retention
About this trial
This is an interventional prevention trial for Urinary Retention focused on measuring Urinary Retention, post surgery Urinary Retention, thoracic surgery, spontaneous voiding, bladder retention, Tamsulosin (FlomaxTM), kidney injury, men undergoing thoracic oncological surgical procedure, BladderScanner
Eligibility Criteria
Inclusion Criteria: Males ≥55 years old Planned thoracic oncological surgical procedure of a video assisted oncological surgical procedure for suspected or confirmed cancer. Surgery scheduled more than 7 days from the time of consent Exclusion Criteria: Using Tamsulosin already Known allergy to Tamsulosin or sulfa drugs Current use of Boceprevir Resting systolic blood pressure <100 Orthostatic hypotension of >20mm Hg systolic and/or 10mm Hg diastolic pressure from sitting to standing (after 2 minutes of standing) as measured at the time of consent Known history of hypotension Known diagnosis of congestive heart failure (CHF) and valvular heart disease History of prior prostate surgery (prostatectomy, trans-urethral resection)
Sites / Locations
- Ocean University Medical Center
- South Ocean University Medical Center
- Jersey Shore University Medical CenterRecruiting
- Riverview Medical Center
Arms of the Study
Arm 1
Experimental
Pre-operative Tamsulosin administration
Subjects will be provided with a prescription for Tamsulosin (generic) to be taken 7 days prior to scheduled surgery for thoracic cancer. Tamsulosin dose is set at 0.4mg/day and should be taken daily for seven days prior to their planned surgery date. Study subjects will also be given a diary to record their daily usage. Study subjects should take Tamsulosin on the day of the surgery with a sip of water.